详情页 - 四川省肿瘤医院知识库

当前位置：首页 > 详情页

Reactivating P53 to treat osteosarcoma: A tetrahedral framework nucleic acids-based approach

文献详情

资源类型：

Pubmed体系：

作者：

机构： [1]Department of Orthopedics, Orthopedic Research Institute, West China Hospital, Sichuan University, Chengdu, 610041, Sichuan, China. [2]State Key Laboratory of Oral Diseases & National Center for Stomatology & National Clinical Research Center for Oral Diseases, West China Hospital of Stomatology, Sichuan University, Chengdu 610041, Sichuan, China. [3]Department of Orthopedics, Hospital of Chengdu Office of People's Government of Tibetan Autonomous Region (Hospital.C.T.), Orthopedic Research Institute, West China Hospital, Sichuan University, Chengdu 610041, China. [4]Department of Orthopaedics (spine surgery), The First Affiliated Hospital of Wenzhou Medical University, Wenzhou, Zhejiang, China. [5]National Clinical Research Center for Geriatrics, Center of Gerontology and Geriatrics, West China Hospital, Sichuan University, No. 37 Guoxue Alley, Wuhou District, Chengdu 610041, China.

出处：

DOI：

ISSN：

关键词： P53 Osteosarcoma Tetrahedral framework nucleic acids

摘要：

Osteosarcoma is a prevalent malignant tumor among adolescents, and the current five-year survival rate of osteosarcoma remains at 70 %, which has not improved in the last three decades. Therefore, there is an urgent need for drugs that can improve the prognosis of osteosarcoma patients. APR-246, also known as Eprenetapopt, is an activator of mutant P53. It has a good effect on promoting apoptosis of osteosarcoma cells, tetrahedral framework nucleic acids (tFNAs) are a small molecule drug delivery system with good biosafety, in order to improve the anti-osteosarcoma efficiency of APR-246, in the present study, a novel nanoparticle T-APR-246 was successfully synthesized using tFNAs to carry APR-246. In vivo and in vitro experiments showed that T-APR-246 more efficiently promoted osteosarcoma cell apoptosis and inhibited osteosarcoma cell proliferation and metastasis than APR-246. Our findings provide new research insights into the treatment of osteosarcoma.Copyright © 2025 Elsevier B.V. All rights reserved.

基金：

语种：

PubmedID：

中科院(CAS)分区：

出版当年[2025]版：

无

最新[2023]版：

大类 | 1 区

化学

小类 | 1 区应用化学 1 区高分子科学 2 区生化与分子生物学

第一作者：

第一作者机构： [1]Department of Orthopedics, Orthopedic Research Institute, West China Hospital, Sichuan University, Chengdu, 610041, Sichuan, China.

共同第一作者：

通讯作者：

通讯机构： [1]Department of Orthopedics, Orthopedic Research Institute, West China Hospital, Sichuan University, Chengdu, 610041, Sichuan, China. [3]Department of Orthopedics, Hospital of Chengdu Office of People's Government of Tibetan Autonomous Region (Hospital.C.T.), Orthopedic Research Institute, West China Hospital, Sichuan University, Chengdu 610041, China.

推荐引用方式(GB/T 7714)：

APA：

MLA：

Reactivating P53 to treat osteosarcoma: A tetrahedral framework nucleic acids-based approach

文献详情

相关文献